Century Therapeutics, Inc.
NASDAQ:IPSCBiotechnology
+$0.01 today
- Market cap
- $250.60M
- Beta
- 1.57
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.25
Volume 1.14M
Average 1.12M
IPSC Total Current Assets
All assets expected to be converted to cash or used up within one year.
Century Therapeutics, Inc.NASDAQ: IPSC
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 18.0% from a year ago
Total current assets stood at $139.04M at the end of Q1 FY2026, down 18.0% from a year earlier and up 15.1% from the prior quarter. Over 3 fiscal years it compounded at -27.7% a year.
Context
- Total current assets amounted to 42.6% of total assets at the end of Q1 FY2026, down 11.2 pp from a year earlier.
- Total current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -18.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 120.77M USD
- Year-over-year change
- -37.8%
- 4-year CAGR
- -14.7%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 120.77M | -37.8% |
| FY2024 | 2024-12-31 | 194.05M | +9.6% |
| FY2023 | 2023-12-31 | 176.99M | -44.6% |
| FY2022 | 2022-12-31 | 319.72M | +40.1% |
| FY2021 | 2021-12-31 | 228.15M | — |
Total Current Assets vs competitors
How IPSC compares with its peers on the latest reported figures
- IPSC's Mar 2026 total current assets of $139.04M is the highest of the 8 companies compared; the peer median is $20.9M.
- Its year-over-year change of -18.0% is the 7th highest of 8, against a peer median of +27.0%.
- Total current assets amounts to 42.6% of total assets for IPSC, versus a peer median of 95.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $139.04M | -18.0% | -27.7% | 42.6% | |
| Mar 2026 | $126.33M | +5.1% | -33.5% | 96.1% | |
| Mar 2026 | $62.28M | +284.0% | -26.7% | 98.7% | |
| Mar 2026 | $26.39M | +65.7% | -21.7% | 85.5% | |
| Mar 2026 | $20.9M | +17.4% | -14.2% | 95.5% | |
| Mar 2026 | $5.91M | +27.0% | +23.1% | 29.9% | |
| Mar 2026 | $5.79M | +1078.7% | +432.1% | 100.0% | |
OSTXOS Therapies Incorporated | Mar 2026 | $917.55K | -77.6% | -12.5% | 12.6% |
| Peer median (excluding IPSC) | $20.9M | +27.0% | -14.2% | 95.5% | |
Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 56.45M | 84.27M | 47.32M | 58.44M | 61.85M |
| Short-term Investments | 166.43M | 231.23M | 125.41M | 130.85M | 55.26M |
| Net Receivables | 250K | 780K | 665K | 1.52M | 667K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.79M | 462K | 1.79M | 860K | 2.99M |
| Total Current Assets | 228.15M | 319.72M | 176.99M | 194.05M | 120.77M |
| Property, Plant & Equipment (Net) | 69.82M | 111.73M | 92.08M | 90.85M | 66.17M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 34.2M | 34.2M |
| Long-term Investments | 135.91M | 51.85M | 91.08M | 30.82M | 2.36M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.49M | 3.24M | 541K | 3.3M | 211K |
| Total Non-current Assets | 209.22M | 166.82M | 183.7M | 159.17M | 102.94M |
| Total Assets | 437.38M | 486.54M | 360.69M | 353.22M | 223.7M |
| Account Payables | 7.6M | 5.45M | 2.74M | 3.08M | 4.77M |
| Short-term Debt | 1.04M | 6.5M | 1.51M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 7.15M | 4.37M | 109.16M | 0 |
| Other Current Liabilities | 1.08M | 3.17M | 2.72M | 82K | 3.78M |
| Total Current Liabilities | 15.66M | 29.82M | 17.85M | 129.78M | 20.23M |
| Long-term Debt | 8.9M | 3.74M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 4.37M | 4.3M |
| Deferred Revenue (Non-current) | 0 | 110.83M | 111.38M | 0 | 0 |
| Other Non-current Liabilities | 2.02M | 718K | 56K | 8.74M | 0 |
| Total Non-current Liabilities | 25.48M | 153.99M | 158.1M | 62.07M | 44.54M |
| Total Liabilities | 41.14M | 183.81M | 175.94M | 191.85M | 64.77M |
| Common Stock | 5K | 6K | 6K | 9K | 9K |
| Retained Earnings | (388.17M) | (519.1M) | (655.77M) | (782.34M) | (791.92M) |
| Accumulated OCI | (650K) | (2.46M) | 108K | 324K | 30K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 396.24M | 302.74M | 184.75M | 161.36M | 158.94M |
| Total Debt | 25.12M | 49.41M | 48.17M | 53.83M | 43.57M |
| Net Debt | (31.33M) | (34.85M) | 847K | (4.61M) | (18.29M) |
Century Therapeutics, Inc.
NASDAQ:IPSC
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.